Rapid occlusion of artificial microvascular grafts (AMGs; £2-mm diameter) by platelet-rich thrombi prevents the clinical use of AMGs in cardiac, vascular, and plastic surgery. Since present antiplatelet agents are unable to assure AMG patency, we have studied the role of specific platelet membrane-glycoprotein blockade on platelet retention by AMGs. In a customized in vitro perfusion chamber, retention on polytetrafluoroethylene (PTFE) AMGs (1.0-mm i.d.) of indiumill-labeled platelets in human whole blood was measured in the presence and absence of inhibitors. Specific blockade of platelet membrane glycoprotein (Gp) Ilb/IIIa was achieved using monoclonal antibody 10E5 (10 /ug/ml) and the peptide GRGDS (Gly-Arg-Gly-Asp-Ser, 0.75 mM). These inhibited 98% and 35%, respectively, of platelet retention under circumstances in which aspirin (7 mM) and dextran (4 mg/ml) inhibited 19% and 18%, respectively, of platelet retention. Nonspecific immunoglobulin G F(ab') 2 (10 /tg/ml) and nonspecific peptide (GGDA; Gly-GlyAsp-Ala, 0.75 mM), used as control reagents, were ineffective in this setting. Monoclonal antibody 6D1 (10 /Ltg/ml), which blocks platelet membrane Gplb, prevented 82% of platelet retention on PTFE. These doses of 10E5 and GRGDS completely inhibited platelet aggregation in response to 20 /uM ADP, and the dose of 6D1 completely inhibited ristocetin-induced platelet agglutination. The aspirin dose prevented the second phase of ADP-induced aggregation. These data indicate that not only does initial platelet adhesion to PTFE require GpUb/IUa but also that Gplb plays a significant role in the early stages of platelet retention on PTFE AMGs. (Arteriosclerosis and Thrombosis 1991;ll:552-560)
gation alone may suffice to prolong patency, since the layer of platelets that truly adheres to the graft wall only minimally encroaches on the relatively large luminal diameter. In AMGs, however, the initial adherent layers of platelets produce a proportionately greater (albeit still minimal) restriction of the lumen. However, they thereby provide a thrombogenic coat with a much shorter mean distance to the centerline of flow. In the remaining small space, their ability to catalyze the generation of thrombin and to recruit additional platelets therefore becomes proportionately more important. 1 -6 We have hypothesized that reliable AMG patency might be achieved either if platelets were prevented from initially adhering to the AMG or if they were restricted only to accumulation as a monolayer. New knowledge regarding platelet adhesive mechanisms implicates the involvement of two membrane glycoprotein (Gp) receptors, GpIIb/IIIa and Gplb. 7 Platelets are thought to adhere to artificial surfaces via an interposed plasma protein coat, enriched in fibrinogen and other plasma proteins, to which the glycoprotein receptors attach. 8 - 10 Using a polyethylene microconduit model, we 11 have recently shown that initial platelet adhesion to an AMG requires GpIIb/ Ilia and fibrinogen, while adhesion of a second platelet layer atop the first requires both Gplb and von Willebrand factor. The present studies address this mechanism using a clinically implantable material, polytetrafluoroethylene (PTFE).
We have measured human platelet retention to PTFE AMGs (1.0-mm-diameter) in vitro after blockade of platelet membrane glycoproteins with specific antibodies and a specific peptide that mimics a portion of the fibrinogen molecule to which platelets bind. 12 Their efficacy is compared with that of standard antiplatelet agents (aspirin, dextran) and appropriate controls. These data indicate the relative power of antiglycoprotein strategies in the inhibition of platelet retention on AMGs. They also support our earlier findings that the initial adhesion of platelets to the surface depends on GpIIb/IIIa. They are also consistent with the hypothesis that Gplb may be required for a second layer of platelets to attach to an initial surface-adherent layer of platelets. These findings may provide unique targets for the restriction of platelet thrombus growth in vivo.
Methods

Materials
PTFE grafts (1.0-mm i.d.) were provided by W.L. Gore and Associates, Inc., Flagstaff, Ariz. Murine monoclonal antibodies 10E5 and 6D1 (which bind to and block platelet membrane GpsIIb/IIIa and Ib, respectively) were kindly provided as F(ab') 2 fragments by Barry Coller, Stony Brook, N.Y. 1314 Azide, 0.05%, was present to preserve the antibodies (2 mg/ml stock). After dilution of the antibodies to 10 p,g/ml, the final azide concentration was 0.0005%, which did not influence platelet retention in this model system (P.C. Johnson et al, unpublished data). Luciferin-luciferase, ristocetin, ADP, aspirin, dextran, scanning electron microscopy (SEM) reagents, and buffer reagents were purchased from Sigma Chemical Co., St. Louis, Mo. GRGDS and GGDA peptides were purchased from Bachem Chemical, Zurich, Switzerland. Nonspecific murine immunoglobulin G (IgG) F(ab') 2 was purchased from Accurate Antibodies, Westbury, N.Y. Polaroid type 55 black-and-white film was used to record electron microscope-generated images. Indium-lll-labeled oxine was obtained from Amersham, Inc., Arlington Heights, 111.
Constituents of A^-(2-hydroxyethyl)piperazine-Af'-(2-ethanesulfonic acid) (HEPES)-Tyrode's (HT) buffer were (mM) NaHCO 3 8.9, KC1 2.8, KH 2 PO 4 0.8, HEPES 10, dextrose 5.6, NaCl 129, and MgCl 2 0.8, with pH equilibrated to 7.4 unless stated otherwise.
Constituents of the SEM fixative were 0.1 mM sodium cacodylate, 2.0% paraformaldehyde, 1.5% glutaraldehyde, and 2.5 mM CaCl 2 , at pH 7.2.
Perfusion Apparatus
A neonatal incubator (Isolette model C-86, Narco Medical, Warminster, Pa.) was custom modified to house two constant-perfusion syringe pumps (models 907 and 975, Harvard Apparatus, South Natick, Mass.). An adjustable-length rack that holds as many as four syringes allowed simultaneous perfusion of multiple test and control AMGs. The PTFE AMG was mounted between three-way stopcocks in line with the bloodcontaining syringe (Figure 1) . A syringe containing HT buffer for a postperfusion flush was mounted on the second Harvard pump and was attached via warmed tubing to the proximal stopcock. The distal stopcock was attached to tubing that was filled with buffer and was suspended at a height of 80 cm. During perfusion, blood and then buffer were discharged through the tubing into a collection receptacle at the top of the column, thereby maintaining a constant 80-cm water transmural pressure at the level of the AMG ( Figure  1 ). Platelet retention under constant flow conditions has recently been shown to be comparable to that seen in pulsatile flow. 15 
Collection of Blood
Nine parts blood from nonmedicated, normal human paid donors was collected by venipuncture into one pan trisodium citrate, 130 mM. Platelet-rich plasma (PRP) was obtained by differential centrifugation at 200g for 13 minutes (model Centra 8-R, International Equipment Corp., Needham, Mass.). After measurement of hematocrit, the packed red blood cells (PRBCs) were incubated at 37°C. The PRP was acidified with 0.04 ml 150 mM citric acid/ml and spun at l,000g for 6 minutes to obtain a soft platelet pellet. Platelet-poor plasma (PPP) was then retrieved, and pH was adjusted to 7.4 with 0.15N NaOH. Platelets were then labeled with '"In as follows. The platelet pellet was resuspended in 1 ml HT buffer, then layered onto a 10-ml column of Sepharose 2B gel preequilibrated with 40 ml HT buffer containing 1 /y,M prostaglandin E 1; pH 6.4. The concentrated suspension of platelets was then layered gently on the column and eluted with HT buffer. Approximately 2 ml buffer containing gel-filtered platelets was collected, to which 60 p,Ci
1H
In-oxine was added. The platelets were then incubated in a water bath at 37°C for 1 minute.
To determine the platelet-specific radioactivity and the labeling efficiency, 50 ii\ of the labeled platelet suspension was spun in an Eppendorf minicentrifuge at 14,000 rpm for 2 minutes. Twenty-five microliters of the supernatant was counted in a Beckman gamma counter (Beckman Instruments, Palo Alto, Calif.), as was an additional 50 fi\ of the labeled platelet suspension. The resulting counts, combined with a platelet count of the diluted suspension (model ZBI, Coulter Electronics, Hialeah, Fla.) enabled us to calculate both the labeling efficiency and the specific activity.
The remaining suspension of labeled platelets was centrifuged at 2,800 rpm for 6 minutes, the supernatant was decanted, and the sides of the tube were washed with PPP, pH 7.4. The labeled platelets were then resuspended to a 25-ml volume with PPP, pH 7.4, and a platelet count was obtained. The platelet count was adjusted to 300,000/p.l with further addition of PPP, pH 7.4, and verified by Coulter count. The labeled platelets were then incubated in a 37°C water bath for 1 hour before aggregation tests and perfusions were performed.
After completion of the incubation period, platelets in PRP were checked for their ability to aggregate and to secTete ATP (luciferin-luciferase assay) in response to ADP (5-20 /iM) and ristocetin (final concentration, 1.8 mg/ml). The aggregation tests were also performed in the presence of the inhibitors after incubation for the same length of time as they were incubated with the platelets before reconstitution as whole blood and perfusion of AMG (Vz hour for aspirin; 5 minutes for all others). Whole blood was then reconstituted by the addition of PRBCs to PRP to achieve a hematocrit of 40.
'"In-labeled platelets have been shown by others to aggregate and secrete granule contents normally in response to agonists, and we corroborated their findings. 16 
Choice of Inhibitor Concentrations
Aspirin. A dose of 7 mM was chosen to completely block the second, arachidonic acid-requiring phase of platelet aggregation in response to ADP. This effect was confirmed by aggregometry.
Dextran. A dose of 4 mg/ml was chosen based on the expected intravascular concentration after routine dosage for microsurgical procedures in which AMGs might be used. 17 Monoclonal antibody 10E5 at 10 iig/m\ and the pentapeptide GRGDS at 0.75 mM completely inhibited aggregation, but not shape change, in response to 20 (iM ADP, a high dose for this agonist. GRGDS is a high-affinity analogue of the RGDS (Arg-Gly-Asp-Ser) amino acid sequence found at one of the platelet binding sites on fibrinogen and on several other adhesive proteins.
-
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' 19 It acts to block GpIIb/IIIa, but not Gplb. Monoclonal antibody 6D1, 10 ^g/ml, completely blocked ristocetin-induced platelet agglutination, a process that requires Gplb plus von Willebrand factor. Control nonspecific antibody (IgG, F[ab'] 2 ) and peptide (GGDA) concentrations were 10 /xg/ml and 0.75 mM, respectively.
Method of Perfusion
Ten milliliters of human whole blood (hematocrit=40) reconstituted with in In-labeled platelets was gently drawn into a plastic syringe and attached via a three-way stopcock to the test AMG in the perfusion chamber (37°C). Perfusions were then performed at a shear rate of 312 sec"
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Each perfusion was performed against an 80-cmwater height of open tubing containing HT buffer, pH 7.4. The AMG was soaked in the same buffer for 10 minutes before use. A control perfusion was run parallel to each test perfusion using blood from the same donor. Immediately on completion of the perfusion, the proximal three-way stopcock was turned, and 5 ml HT buffer, pH 7.4, was perfused through the tubing at the same shear rate as that of the blood perfusion. SEM revealed no RBCs on the remaining surface, indicating the effectiveness of the flush. In all cases, the AMG was divided into 1-cm segments that were counted individually (1 minute) in a Beckman Model 5500 gamma counter.
Preparation of Artificial Microvascular Grafts for Scanning Electron Microscopy Evaluation
After initial fixation of the AMGs for at least 1 day in SEM fixative, they were dehydrated in graded ethanol concentrations, mounted on aluminum stubs, criticalpoint dried (Samdri-Regulated, Tsousimis Research Corp., RockvUle, Md.), and sputter coated with gold for 2 minutes (Hummer VI D/C Sputter Coating System, Technics, Dublin, Calif.). AMG segments were examined in a JEOL Series 300 SEM at an operating voltage of 20 kV at 1,000-5,000 magnification. Sites for photographic documentation were chosen at random while scanning under low power, then magnified and recorded. Polaroid type 55 black-and-white film was used.
Data Collection/Statistical Analysis
All tubing gamma counts were entered into a SYMPHONY spreadsheet template, which automatically calculated the number of platelets per square centimeter of AMG surface, and normalized the number of platelets per square centimeter on test AMGs versus their respective same-day/same-donor controls. Normalization of data by the latter method is necessary to allow comparison of interindividual data for which the absolute numbers of bound platelets may differ. Dispersion of the control values was calculated by first dividing each control value by the mean of the controls for that person's blood. In this way, a ratio that controlled for both test and control segments was used to perform a Welch-Aspen test for the equality of means. This was rejected (p=0.0000). Therefore, Dunnett's procedure was employed for post-hoc comparisons. Since all controls are normalized to a mean of 1, they were pooled for this comparison, and this accounts for the large number of controls (n=34) to test samples (n~6 each), BMDP statistical software was used on a Model 50 IBM PS/2 computer for all calculations.
Results
Platelet Aggregation in the Presence of Inhibitors
Platelet aggregation in response to ADP and ristocetin was measured for each donor's platelets in the presence and absence of inhibitors. Antibody 10E5 and peptide GRGDS inhibited platelet aggregation (but not shape change) in response to ADP, whereas they had no effect on ristocetin-induced platelet agglutination. Conversely, antibody 6D1 inhibited ristocetin-induced agglutination while failing to inhibit ADP-induced platelet aggregation. These data corroborate the work of others.
14 Aspirin (7 mM) partially inhibited ADP-induced platelet aggregation but not ristocetin-induced agglutination. Dextran was ineffective in either setting, as were the control nonspecific antibody and peptide (Figures 2 and 3) . 
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Platelet Retention on Pofytetrafluoroethylene Artificial Microvascular Grafts
Thirty-four 10-cm segments of 1-mm-diameter PTFE were perfused with human whole blood containing no platelet inhibitors during the course of this study. The average absolute number of platelets per square centimeter of PTFE surface (measured at the central 1-cm segment) was 2.68xlO 6 ± 1.02x10*. This includes data from all donors, thereby providing an estimate of the interindividual variation in platelet adhesion to PTFE. The mean intraindrvidual variation is indicated by the error bar in the graph of control platelet adhesion (Figure 4 ; SD=17%). A minimum of two control perfusions were performed per donor per day, but in most cases, each test perfusion was performed side by side with a control perfusion. All test perfusion results were normalized as a ratio to that of their same-day/same-donor controls. SEM analysis of control tubing revealed retained platelets in multiple stages of activation ( Figure 5 ). All SEM and retention data represent that seen on the central 1 cm of the AMG. The variance of the data obtained at this segment was equal to that of each of the other nine segments (analysis of variance, p=0.97).
Effects of Aspirin and Dextran on Platelet Retention
Aspirin (7 mM) and dextran (4 mg/ml) reduced platelet retention on the PTFE AMG (H=6,/?<0.05; Figure 4 ). Although reduced in number, individual retained platelet morphology was unchanged relative to controls ( Figure 5 ).
Effects of Antibody Inhibition of Membrane Gfycoproteins Ib and Ilb/IIIa
Monoclonal antibody 6D1, directed against Gplb, inhibited 82% of "'In-labeled platelet retention in this model (n=6, p<0.01 vs. control; Figure 6 ). In SEM observations, platelet number was markedly reduced, and individual retained platelet morphology revealed an absence of platelet aggregation atop surface-attached platelets ( Figure 5 ). Antibody 10E5, directed against GpIIb/IIIa, inhibited more than 98% of platelet retention relative to controls (n=6, p<0.0l vs. control; Figure 6 ). This is corroborated by the sparse population of surface-attached platelets seen on SEM ( Figure 5 ). The control antibody did not inhibit platelet retention relative to the untreated control and did not alter the retained platelet morphology ( Figure 7 ). Antibody 10E5 therefore appears to be a true adhesion blocker, whereas antibody 6D1 may block the first step in aggregation of additional platelets onto surface-attached platelets.
Effects of Site-Specific Peptide Inhibition ofGpIIb/IIIa
Peptide GRGDS, a high-affinity mimic of one portion of fibrinogen that binds to GpIIb/IIIa, partially inhibited platelet retention on PTFE (n=6, p<0.05 vs. control) but lacked the inhibitory power of antibody 10E5, despite their equivalent ability to inhibit platelet aggregation (Figures 2 and 7) . This further demonstrates that the ability of a drug to inhibit aggregation does not necessarily correlate with the degree of its ability to inhibit platelet adhesion. 18 Peptide GRGDS did not alter the morphology of the individual retained platelets, although they were reduced in number. The nonspecific peptide did not inhibit platelet retention and did not alter retained platelet morphology (Figure 7 ).
Discussion
We 1121 have shown in previous studies of platelet retention on polyethylene-100 microconduits that selective platelet membrane glycoprotein blockade disrupts vertical platelet thrombus growth at discrete levels. Those data suggested that platelet adhesion to an artificial surface could be inhibited by antibody 10E5 and kept at a monolayer by antibody 6D1. Since these therapies may have merit under certain clinical circumstances, including the bypass of distal atherosclerotic lesions with small vascular grafts, a clinically relevant material was chosen for further study. PTFE has been shown to be a relatively nonthrombogenic material for large-vessel replacement (>4-mm-diameter), but attempts to use smaller-diameter PTFE vessels in humans have proven unreliable. 22 Similarly, when PTFE AMGs (<2-mm-diameter) have been used at multiple anatomic sites in animals, patency rates have been shown to vary widely. 3 Patency rates have been improved by the administration of antiplatelet agents but not to a degree sufficient to allow their clinical use in humans. 3 Even in the absence of technical errors, AMGs occlude easily because they constitute an environment in which the artificial surface-to-blood volume ratio is high. This accentuates the probability that platelets will interact with the artificial surface, leading eventually to an obstructing platelet thrombus. Such a thrombus begins with an initial layer of adherent platelets onto which additional platelets are recruited.
In such small-diameter vascular grafts, it is theoretically attractive to prevent the development of a platelet thrombus through inhibition of the initial platelet adhesion step. One reason why present clinically available antiplatelet therapy has incomplete efficacy in this setting is that agents such as aspirin and dextran are only modestly able to influence the adhesion step, which may be a more critical determinant of AMG patency than of larger graft patency. For example, dextran has been shown to provide a striking improvement in the early patency of distal extremity bypass with larger PTFE grafts in humans and to reduce platelet retention by PTFE shunts in baboons. 23 - 24 In our AMG model, dextran had only a minimal inhibitory effect on the early stages of platelet retention, in which adhesion plays a larger role.
The flow rate and shear rate examined in these experiments reside on the lower end of the physiological scale, but they do represent values relevant to the caliber of the vessels used in microsurgery (0.1 cm). 25 It is likely that this flow/shear combination has special relevance to the low flow rates seen in the first several minutes after clamp removal in microsurgery, a period of high risk for thrombosis. 3 -26 Also, the decline in retention seen at higher flow/shear combinations may be artifactual in that platelets on an artificial surface are known to have a high rate of embolism, as demonstrated in systems that directly view fluorescence of labeled platelets in flow. 20 This phenomenon has also been shown to occur in vivo. 26 At low shear rates, as studied here, platelets remain on the AMG in significant numbers, and therefore low flow may also represent the state of highest risk in vivo when an AMG is present.
New knowledge regarding the mechanisms of platelet adhesion to natural and artificial surfaces has led to the development of specific antireceptor antibodies and peptides that are effective in either setting. Platelets bind to exposed subendothelium with a variety of receptors (GpIa/IIa, Gplb, GpIIb/IIIa), whose involvement depends on local flow conditions. 27 - 28 For example, platelets may bind to subendothelium through Gplb via von Willebrand factor, which is attached to collagen (high shear rate), directly to collagen via GpIa/IIa (low shear rate), or via GpIIb/ Ilia, which may bind to fibronectin, vitronectin, von Willebrand factor, or fibrinogen present at varying concentrations in the subendothelium. Platelet adhesion to an artificial surface may occur through a less complex mechanism. Initial platelet adhesion in this setting occurs almost solely via GpIIb/IIIa, presumably by attachment to surfacebound fibrinogen and other ligands.
11
- 21 As shown in this study, blockade of GpIIb/IIIa by a specific antibody can almost completely inhibit the adhesion of platelets to an AMG during the first 6 minutes of flow. During the same interval, both aspirin and dextran at clinically relevant concentrations significantly but only modestly reduce platelet retention. Monoclonal antibody 6D1, which blocks Gplb, was also able to reduce platelet retention, but not as completely as did 10E5. This finding and the platelet morphology seen on SEM photomicrographs are consistent with our findings in earlier experiments in which a polyethylene AMG was perfused. 1121 In that model, further investigation revealed that the major effect of blockade of Gplb was to prevent the accumulation of additional platelets atop the initially adherent layer. Platelet adhesion was thereby restricted to a monolayer, that is, a truly adherent layer.
The site-specific peptide GRGDS, which impairs the binding of several adhesive proteins to GpIIb/IIIa, was not as powerful an adhesion inhibitor as antibody 10E5, which also acts by blocking GpIIb/HIa. It is known that the fibrinogen molecule is able to bind to GpIIb/ILIa at a minimum of two types of sites, only one of which is mimicked by GRGDS. 1819 Our data may indicate that surface-bound fibrinogen is able to bind to platelet GpIIb/IIIa via the second mechanism (i.e., via the carboxy terminus of the fibrinogen y-chain) in the presence of GRGDS, but not in the presence of the larger antibody molecule. It is of interest that platelet aggregation, a process that occurs when adjacent platelets bind a common fibrinogen molecule, is equally inhibited by both GRGDS and 10E5 at the concentrations used in this study. That 10E5 is a more powerful inhibitor of platelet adhesion than GRGDS indicates that platelet adhesion to an artificial surface is a distinct process that cannot be equated with platelet aggregation, despite their apparently common receptor-ligand requirements. 18 The specificity of these responses is indicated by the results obtained with matched molecule peptide and antibody controls, similar except for their specific binding capabilities, in the peptide and antibody experiments, respectively.
In conclusion, we have shown that platelet retention on a PTFE AMG can be nearly prevented using specific antiglycoprotein reagents under circumstances in which standard antiplatelet therapy shows only a partial effect. This model has clinical relevance in that human blood is used, and the earliest potential clinical events are studied. The type and geometry of the AMG are also clinically relevant, especially to microsurgeons. 3 Interpretation of these results must be tempered by the fact that anticoagulated blood is used to isolate the platelet-related events. The role of thrombin is not investigated here, although it is reasonable to expect that thrombin, a powerful platelet agonist, will also play a role in early AMG occlusion. Although concurrent platelet secretion studies were not performed, such studies would help to determine the role of secreted ADP in the adhesive responses observed. 29 It remains to be determined if antithrombotic agents (such as heparin or hirudin) will be needed to approximate these results in vivo. Also, since these experiments describe platelet retention after short exposure times only, they do not answer the allimportant question of patency time in vivo.
